首页|MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma
MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Osteosarcoma is a malignant bone tumor in which the survival rate is still low。 MicroRNA-326 (miR-326) has been proved a potential diagnostic and prognostic marker for several tumors。 However， the clinical value of miR-326 is still unknown。 In the present study， we detected the expression of miR-326 in the serum of osteosarcoma patients and in osteosarcoma tissues using qRT-PCR。 We compared the serum expression of miR-326 with the clinicopathological characteristics and survival of osteosarcoma patients。 Finally， we explored the role of miR-326 of the invasion of osteosarcoma tumor cells using cell migration and invasion assays。 We found that the expression of miR-326 was significantly decreased in the serum of osteosarcoma patients and osteosarcoma tumor cells compared to healthy controls (P < 0。01)。 Moreover， a receiver operating characteristic (ROC) curve analysis is indicated that serum miR-326 is a potential diagnostic marker of osteosarcoma with an area under the ROC curve of 0。817。 Importantly， patients with a lower expression of miR-326 tended to have distant metastasis (P < 0。05) and a more advanced clinical stage (P < 0。05)。 In addition， the survival time of patients with depressed miR-326 expression was significantly shorter compared to patients with high miR-326 expression (P < 0。05)。 Further-more， we found that miR-326 could inhibit the proliferation， migration and invasion of osteosarcoma cells。 Thus， we demonstrated that miR-326 might be related to the metastasis of osteosarcoma and could be used as a potential diagnostic and prognostic biomarker in osteosarcoma。 (C) 2016 Elsevier Masson SAS。 All rights reserved。
NSTL
Elsevier
